Gamma amino butyric acid - Diamyd

Drug Profile

Gamma amino butyric acid - Diamyd

Alternative Names: GABA - Diamyd; Remygen

Latest Information Update: 06 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Diamyd Medical AB
  • Developer Diamyd Medical AB; Uppsala University Hospital
  • Class Antihyperglycaemics
  • Mechanism of Action GABA agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Type 1 diabetes mellitus

Most Recent Events

  • 04 Jul 2018 Diamyd Medical completes enrolment in its phase I trial for Type-1 diabetes mellitus in USA (NCT02002130)
  • 13 Jun 2018 Swedish Medical Products Agency approves IND application for phase I/II ReGenerate-1 trial in Type-1 diabetes mellitus
  • 05 Jun 2018 Phase-I/II clinical trials in Type-1 diabetes mellitus in Sweden (PO) (EudraCT2018-001115-73)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top